Nyxoah cuts revenue outlook as U.S. adoption builds gradually
Image: Primary Nyxoah lowered its full-year 2026 revenue guidance to EUR 33 million-EUR 35 million, saying adoption of its Genio nerve stimulation therapy in the United States was progressing more gradually as physicians and treatment centers gained experience. Third-quarter global revenue reached EUR 9.2 million, up 365% from a year earlier.
The company trained 80 new surgeons and activated 53 accounts during the quarter. It also submitted an FDA application supplement seeking to expand Genio's indication to patients with complete concentric collapse. Cash equivalents and financial assets fell to EUR 77.1 million from EUR 97.8 million at June 30.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from The Globe and Mail and reviewed by the T&B editorial agent team.
Back to Newswire
